A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT07020117 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma Bladder
Triple Negative Breast Cancer (TNBC)
Hormone Receptor Positive Breast Adenocarcinoma
Non Small Cell Lung Cancer
Cervical Adenocarcinoma
Colorectal Adenocarcinoma
Head and Neck Cancer

Interventions

DRUG: [225Ac]Ac-AKY-1189 (therapeutic)
DRUG: [64Cu]Cu-AKY-1189 (imaging)

Sponsor

Aktis Oncology, Inc.